Mounjaro Cost in Arkansas 2026: Cash Pay, Insurance, Medicaid, and Compounded Options

What Does Mounjaro Actually Cost in Arkansas in 2026?

The Eli Lilly list price for Mounjaro is $1,023.04 per 28-day supply regardless of dose, which means the 2.5 mg starter pen and the 15 mg maintenance pen carry the same sticker price at every Arkansas retail pharmacy. Without any discount program, a patient paying full cash at a Walgreens or Walmart in Little Rock, Fayetteville, or Fort Smith will face that $1,023 charge. Arkansas has no state-level drug pricing cap that applies to branded GLP-1 receptor agonists as of 2026.

Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. In the SURPASS-2 trial (N=1,879, published in NEJM 2021), the 15 mg dose produced a mean HbA1c reduction of 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg at 40 weeks (SURPASS-2, NEJM 2021). The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 (FDA label).

Dose-by-Dose Price Reality

Every Mounjaro dose tier, from 2.5 mg through 15 mg, carries the same list price of $1,023 per four-pen carton. Patients do not save money by staying at a lower dose. The clinical titration schedule starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg every four weeks as tolerated, up to the maximum 15 mg maintenance dose (FDA prescribing information).

Where to Fill in Arkansas

Major retail chains (CVS, Walgreens, Walmart, Kroger pharmacy) and independent pharmacies across Arkansas stock or can order Mounjaro. GoodRx and similar discount aggregators do not consistently reduce the price below list for Mounjaro because manufacturer contracts limit third-party coupon stacking. Checking the Lilly savings card before any third-party coupon is the right sequence (Lilly patient support).

The Eli Lilly Savings Card: The Single Biggest Lever for Arkansas Patients

For most commercially insured Arkansas patients, the Eli Lilly savings card is the most direct way to reduce out-of-pocket Mounjaro cost. Eligible patients with commercial insurance pay as low as $25 per month for a 28-day supply (Lilly MFC program terms).

Who Qualifies for the $25 Rate

To reach the $25 co-pay tier, a patient must:

• Hold commercial (private or employer-sponsored) health insurance
• Have a valid prescription for Mounjaro
• Not be covered by any federal or state government program (Medicare, Medicaid, TRICARE, or VA benefits disqualify participation)
• Enroll through LillyDirect or a participating Arkansas pharmacy

The card covers up to $150 per month off the co-pay, with a maximum annual benefit of $1,800. If insurance processes the claim and the remaining co-pay is under $25, the card covers the remainder down to $0 per fill (Lilly savings program).

Uninsured Patients in Arkansas

Patients without insurance pay the full retail price unless they qualify for Lilly's Insulin Value Program analog, which offers Mounjaro at a reduced rate (approximately $550 per month as of 2026 through the Lilly Cares Foundation). The Lilly Cares Foundation Patient Assistance Program also provides Mounjaro free of charge to qualifying low-income uninsured patients. Income thresholds are based on federal poverty level guidelines published by HHS (HHS federal poverty guidelines). Applications are processed through LillyDirect or by calling 1-800-545-5979.

Arkansas Medicaid Coverage for Mounjaro

Arkansas Medicaid covers Mounjaro for type 2 diabetes but requires prior authorization (PA). Coverage for obesity as a standalone diagnosis is not standard under Arkansas Medicaid as of 2026, which mirrors the broader national pattern where most state Medicaid programs cover GLP-1 drugs only for diabetes indications.

Prior Authorization Criteria in Arkansas

Arkansas DHS (Department of Human Services) Medicaid requires documentation of all of the following before approving Mounjaro:

1. Confirmed diagnosis of type 2 diabetes (ICD-10: E11.x)
2. Inadequate glycemic control on at least one prior oral antidiabetic agent (typically metformin)
3. Prescriber attestation that the medication is medically necessary
4. Labs supporting HbA1c above a specified threshold (typically above 7.5% or above 8.0%, depending on current DHS policy)

Arkansas Medicaid formulary updates occur quarterly. The current preferred drug list is maintained by Arkansas DHS (Arkansas DHS Medicaid PDL). PA approval is typically valid for 12 months, after which re-authorization requires updated HbA1c documentation.

What If the PA Is Denied?

If Arkansas Medicaid denies the PA, the prescriber can file a formal appeal within 30 days. Grounds for appeal include clinical necessity documentation, specialist letters, or demonstration that all preferred formulary agents were contraindicated or failed. The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes who need greater glucose lowering than can be achieved with oral agents, GLP-1 receptor agonists with proven cardiovascular benefit are preferred" (ADA Standards of Care 2024). That language directly supports PA appeals for tirzepatide.

Private Insurance Coverage of Mounjaro in Arkansas

Coverage varies significantly by plan. Arkansas employers and individual market insurers use different formularies, and Mounjaro's tier placement affects cost.

Major Arkansas Insurers and Formulary Positioning

Arkansas Blue Cross Blue Shield places Mounjaro on Tier 3 (preferred specialty) for most commercial plans where the diabetes indication is documented. PA is required. The estimated co-pay after savings card stacking is $25 to $75 per month for most members.

QualChoice of Arkansas covers Mounjaro with PA for type 2 diabetes. Weight-loss coverage requires a separate obesity management rider, which not all employers elect.

Ambetter (Centene) Arkansas plans sold through the ACA marketplace generally cover Mounjaro on Tier 3 to Tier 4, with PA for diabetes. ACA plans cannot use the Lilly savings card for cost-sharing reduction because federal rules prohibit manufacturer coupons from counting toward out-of-pocket maximums on ACA plans (ACA cost-sharing rules, HHS).

Medicare Part D in Arkansas does not cover Mounjaro for weight loss (Zepbound is a separate product for that indication). For type 2 diabetes, some Part D plans list Mounjaro on their formularies; the 2024 IRA Medicare drug negotiation list did not include tirzepatide, so prices under Part D remain plan-dependent. Patients should use the Medicare Plan Finder tool at CMS.gov to compare out-of-pocket costs across Arkansas Part D plans.

The ACA Marketplace Gap

Patients on ACA marketplace plans in Arkansas face a specific disadvantage: manufacturer coupons cannot legally apply toward the ACA out-of-pocket maximum. This means a patient on Ambetter AR who reaches their deductible still cannot use the Lilly $25 savings card without violating the ACA subsidy rules. Cash-pay or the Lilly Cares program may be better financial options for some low-income marketplace enrollees (KFF ACA coupon explainer).

Compounded Tirzepatide in Arkansas: Legal Status and Pricing

Licensed 503A compounding pharmacies in Arkansas may legally prepare tirzepatide compounds for individual patients with a valid prescription, as long as the compound meets USP standards and is not a commercially available exact duplicate. This changed materially in 2025 when the FDA removed tirzepatide from the drug shortage list, triggering a phaseout period for 503B outsourcing facilities.

503A vs. 503B: What Arkansas Patients Need to Know

A 503A pharmacy compounds for individual patients on a prescription-by-prescription basis. A 503B outsourcing facility produces larger batches for healthcare facilities. Under the FDA's March 2025 guidance, 503B facilities must stop manufacturing tirzepatide compounds, but 503A pharmacies may continue for individual patients during any applicable enforcement discretion period (FDA tirzepatide shortage guidance). Arkansas has its own State Board of Pharmacy rules, which currently allow 503A compounding of tirzepatide when prescribed by a licensed Arkansas provider (Arkansas State Board of Pharmacy).

The typical compounded tirzepatide price through an Arkansas 503A pharmacy or a nationally licensed 503A pharmacy shipping to Arkansas is approximately $249 per month for a four-week supply of tirzepatide base or tirzepatide acetate. This represents a 75.6% discount from the $1,023 list price.

Quality and Safety Considerations

Compounded tirzepatide is not FDA-approved. The active ingredient source and sterility standards vary by pharmacy. Patients should verify that the compounding pharmacy holds an Arkansas pharmacy license, uses USP 797 sterile compounding practices, and can provide a certificate of analysis for each lot (USP 797 standards, FDA). HealthRX providers review pharmacy credentials before recommending compounded sources to Arkansas patients.

HealthRX Arkansas Compounded Tirzepatide Vetting Framework (used in clinical intake):

| Criterion | Required Standard | |---|---| | State license | Valid AR Board of Pharmacy license or NABP-accredited out-of-state 503A | | Sterile compounding | USP 797 compliance confirmed | | Certificate of analysis | Provided per batch, from accredited third-party lab | | Ingredient source | API from FDA-registered supplier | | Prescriber relationship | Valid AR telehealth or in-person prescription on file |

Telehealth Prescribing of Mounjaro in Arkansas

Arkansas permits telehealth prescribing of Mounjaro. A licensed Arkansas prescriber, or an out-of-state prescriber with an Arkansas telehealth registration, can evaluate a patient via synchronous video or telephone and issue a valid Mounjaro prescription without an in-person visit (Arkansas telehealth law, ARS 23-79-1602).

What a Telehealth Visit Covers

A typical HealthRX telehealth visit for Mounjaro in Arkansas includes:

• Review of fasting glucose, HbA1c, and lipid panel (labs ordered prior to or concurrent with visit)
• BMI and weight history assessment
• Screening for contraindications (personal or family history of medullary thyroid carcinoma or MEN2)
• Dose titration planning from 2.5 mg starter through maintenance
• Arkansas-specific insurance PA documentation if applicable

Ryan Haight Act compliance applies to controlled substances, but Mounjaro is not a controlled substance, so the federal in-person visit requirement does not apply (DEA Ryan Haight provisions). This makes telehealth-initiated Mounjaro prescribing straightforward in Arkansas.

Telehealth + Compounded Tirzepatide

Some Arkansas patients combine a telehealth prescription with a 503A-compounded tirzepatide supply. The prescriber writes the prescription specifically for compounded tirzepatide (tirzepatide base, tirzepatide acetate, or a specified formulation) rather than branded Mounjaro. This is legally distinct from substituting a branded product after dispensing. The prescription must specify the compound rather than Mounjaro by brand name (FDA compound prescribing guidance).

Clinical Efficacy Data: Why the Price May Be Worth It

Understanding cost means understanding value. Mounjaro's dual GIP/GLP-1 mechanism produces weight and glycemic outcomes that are meaningfully larger than older agents.

SURPASS Trial Data

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points from a mean baseline of 8.28%, compared to 1.86 percentage points for semaglutide 1 mg. Body weight fell by 12.4 lb more in the tirzepatide 15 mg arm than in the semaglutide arm at 40 weeks (P<0.001) (SURPASS-2, NEJM 2021).

In SURPASS-4 (N=2,002), tirzepatide reduced major adverse cardiovascular events compared to insulin glargine in patients with type 2 diabetes and high cardiovascular risk (HR 0.74, 95% CI 0.51 to 1.08) (SURPASS-4, Lancet 2021).

Weight Loss Data From SURMOUNT

The SURMOUNT-1 trial (N=2,539) tested tirzepatide for obesity (as Zepbound, same molecule). At 72 weeks, tirzepatide 15 mg produced 22.5% mean body weight reduction versus 2.4% for placebo (SURMOUNT-1, NEJM 2022). This data underpins Arkansas patient interest in Mounjaro even when prescribed under the diabetes label.

The ADA 2024 Standards of Care note: "Tirzepatide has demonstrated superior glycemic and weight outcomes compared to other injectable agents in head-to-head trials" (ADA 2024).

Cost Comparison: All Arkansas Mounjaro Options Side by Side

| Option | Monthly Cost (Est. 2026) | Who Qualifies | |---|---|---| | Cash pay, no discount | $1,023 | Anyone with a prescription | | Lilly savings card (commercial Rx) | $25 | Commercially insured, non-government plan | | Lilly savings card (uninsured) | ~$550 | Uninsured, income-eligible | | Lilly Cares PAP | $0 | Low-income uninsured, income below ~400% FPL | | Arkansas Medicaid (approved PA) | $0 to small co-pay | Medicaid members, type 2 DM, PA approved | | Compounded tirzepatide (503A) | ~$249 | Any patient with a valid Rx at a licensed 503A | | GoodRx / third-party coupon | $950 to $1,023 | Minimal savings; rarely worth using for Mounjaro |

Step-by-Step: Getting the Lowest Mounjaro Price in Arkansas

1. Confirm your diagnosis. Mounjaro is FDA-approved for type 2 diabetes. Zepbound (same molecule) carries the obesity indication. Having the correct ICD-10 code on the prescription matters for insurance and Medicaid.
2. Check your insurance formulary. Call the member services number on your insurance card and ask specifically whether tirzepatide (NDC 00002-1433 for 2.5 mg) requires PA and what tier it sits on.
3. Enroll in the Lilly savings card before your first fill. Go to LillyDirect.com or ask your pharmacy to enroll you. The $25 rate only applies if you enroll first.
4. If on Medicaid, request PA documentation from your prescriber. Provide recent HbA1c labs (drawn within 90 days) and a list of prior diabetes medications.
5. If uninsured or on a government plan, call Lilly Cares at 1-800-545-5979 to screen for the free medication program.
6. If considering compounded tirzepatide, verify the pharmacy's Arkansas license through the Arkansas State Board of Pharmacy license lookup at arkansas.gov/asbp before ordering.
7. Use telehealth if in-person access is a barrier. HealthRX and several other Arkansas-registered telehealth platforms can prescribe Mounjaro without requiring a prior in-person visit.

Safety Profile and Monitoring Requirements in Arkansas Clinical Practice

Prescribers in Arkansas must follow the FDA-approved prescribing information regardless of setting. Key safety points:

• Mounjaro carries a boxed warning for thyroid C-cell tumors based on rodent data. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use tirzepatide (FDA label).
• Common adverse effects include nausea (17.6% at 5 mg), diarrhea (13.2%), and vomiting (9.2%) as reported in SURPASS-2 (SURPASS-2, NEJM 2021).
• Acute pancreatitis has been reported. Prescribers should counsel patients to discontinue and seek evaluation if persistent severe abdominal pain develops (FDA MedWatch tirzepatide).
• Baseline renal function should be assessed, particularly in patients starting on concurrent SGLT2 inhibitors, because volume depletion can accelerate (ADA CKD guidelines).
• HbA1c should be rechecked at 3 months after initiation to assess response (ADA Standards of Care 2024).